6:2 Cl-PFAES
Based on 4 publication(s) in Google Scholar
6:2 Cl-PFAES is an orally effective alternative to Perfluorooctane sulfonate. 6:2 Cl-PFAES significantly inhibits the growth of zebrafish and induces reproductive toxicity. 6:2 Cl-PFAES reduces the relative weights of epididymis and testis in male BALB/c mice. 6:2 Cl-PFAES can be used in the chrome plating industry.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.98%
- CAS. Nr.: 73606-19-6
- Formel: C8ClF16KO4S
- Molecular Weight:570.67
-
Speicherung:
Store at room temperature, keep dry and cool.
In solvent -80°C, 1 year , -20°C, 6 months
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) 6:2 Cl-PFAES
More
Biologische Aktivität
6:2 Cl-PFAES (0.04-1.0 mg/kg/d; p.o.; daily; 56 days) reduces relative testis weight by 8% and absolute/relative epididymis weights by 14% and 16%, respectively, at the highest dose of 1.0 mg/kg/d, but does not alter reproductive hormones, histopathology, sperm quality, fertility, or testicular gene/protein expression in adult male BALB/c mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Tüebingen (5-month-old sexually mature adults, F0 generation; F1 and F2 generations derived from F0 fish)[1]
-
Dosage:5 μg/L; 50 μg/L; 500 μg/L
-
Administration:waterborne; continuous; 180 days (F0 generation); no direct exposure (F1 and F2 generations, maternal transfer)
-
Result:Significantly reduced body weight, body length, condition factor, and gonadosomatic index (GSI) in both sexes of F0 zebrafish at 5 and 50 μg/L.
Caused 85% mortality in male F0 zebrafish at 500 μg/L, with surviving fish unable to reproduce.
Reduced egg production per female F0 zebrafish at 5 and 50 μg/L.
Significantly increased serum testosterone, estradiol, and vitellogenin levels in male F0 zebrafish at 5 μg/L, and increased serum testosterone levels in female F0 zebrafish at 5 and 50 μg/L, altering T/E2 ratios.
Induced gonadal histological changes in F0 zebrafish at 5 and 50 μg/L: testes developed lacunae and reduced mature spermatocytes; ovaries had reduced mature oocytes.
Altered transcriptional levels of multiple hypothalamic-pituitary-gonadal (HPG) axis genes in F0 zebrafish at 5 and 50 μg/L, with down-regulation of brain genes (e.g., gnrh3, fshb, lhb) in most cases, and altered gonadal steroidogenic gene expression (e.g., increased cyp19a in testes, increased hmgra, star, cyp17 in ovaries).
Induced 1576 differentially expressed genes in testes of F0 zebrafish at 50 μg/L, enriched in pathways related to spermatogenesis (e.g., cytokine-cytokine receptor interaction, lysosome, focal adhesion).
Significantly reduced body weight, body length, and female GSI in F1 offspring from 5 μg/L exposed F0 parents; reduced serum testosterone levels in male F1 offspring.
Increased embryo malformation rate to 9.0% and 15.0% at 120 hpf, and increased mortality rates at 120 hpf in F1 offspring from 5 and 50 μg/L exposed F0 parents; F1 offspring from 50 μg/L exposed F0 parents died before 15 dpf.
Detected target reagent in adult blood (0.31 ng/mL males, 0.37 ng/mL females) and gonads (0.10 ng/mg males, 0.12 ng/mg females), and reduced mature oocytes in ovaries of F1 offspring from 5 μg/L exposed F0 parents.
Increased embryo malformation rate to 5.0% at 120 hpf and reduced survival rate in F2 offspring from 5 μg/L exposed F0 parents.
-
Animal Model:BALB/c (male, 6-8 weeks old)[2]
-
Dosage:0.04 mg/kg/d; 0.2 mg/kg/d; 1.0 mg/kg/d
-
Administration:p.o.; daily; 56 days
-
Result:Decreased relative testis weight by 8% in the 1.0 mg/kg/d group compared to control.
Decreased absolute epididymis weight by 14% in the 1.0 mg/kg/d group compared to control.
Decreased relative epididymis weight by 16% in the 1.0 mg/kg/d group compared to control.
Reached serum 6:2 Cl-PFAES levels of 5.89 μg/mL (0.04 mg/kg/d), 18.89 μg/mL (0.2 mg/kg/d), and 58.33 μg/mL (1.0 mg/kg/d).
Reached testis 6:2 Cl-PFAES levels of 5.6 μg/g (0.04 mg/kg/d), 14.4 μg/g (0.2 mg/kg/d), and 49.93 μg/g (1.0 mg/kg/d), representing 5.9×103-, 1.5×104-, and 5.3×104-fold increases over control (0.95 ng/g).
Reached epididymis 6:2 Cl-PFAES levels of 1.69 μg/g (0.04 mg/kg/d), 2.68 μg/g (0.2 mg/kg/d), and 9.64 μg/g (1.0 mg/kg/d), representing 26.1-, 41.4-, and 149-fold increases over control (0.065 μg/g).
Showed no significant changes across all doses in serum or testicular testosterone, estradiol, follicle-stimulating hormone, or luteinizing hormone levels; testis/epididymis histopathology; sperm count; fertility metrics (mating index, litter size, pup birth/weaning weight, pup sex ratio); testicular gene expression profiles; or testicular levels of steroidogenic proteins (STAR, CYP11A1, CYP17A1, 3β-HSD) or cell junction proteins (occludin, β-catenin, connexin 43).
Chemical Information
-
CAS. Nr. 73606-19-6
-
Appearance Solid
-
Molecular Weight 570.67
-
Formel C8ClF16KO4S
-
Color Colorless to off-white
-
SMILES
O=S(C(F)(C(F)(OC(F)(C(F)(C(F)(C(F)(C(F)(C(F)(Cl)F)F)F)F)F)F)F)F)(O[K])=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Store at room temperature, keep dry and cool
In solvent -80°C 1 year -20°C 6 months
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Environ Sci Technol
Integrating Adverse Outcome Pathway-Bayesian Network and Physiologically Based Pharmacokinetic Modeling for Quantitative Prediction of Developmental Neurotoxicity of F-53B under Human-Relevant Exposure Scenarios. [Abstract]2026 May 19;60(19):13911-13924. PMID: 42083094 -
Ecotoxicol Environ Saf
The environmental pollutant F-53B accelerates triple-negative breast cancer progression through metabolic reprogramming. [Abstract]2025 Dec 15:309:119536. PMID: 41401551 -
Chem Biol Interact
F-53B triggers ovarian granulosa cell senescence and ovarian dysfunction by triggering mitochondrial dysfunction. [Abstract]2026 Jan 5:423:111791. PMID: 41241170 -
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (175.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.38 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.38 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (281 KB)
-
SDS (624 KB)
- English - EN (624 KB)
- Français - FR (624 KB)
- Deutsch - DE (624 KB)
- Norwegian - NO (624 KB)
- Español - ES (624 KB)
- Swedish - SV (624 KB)
- Italian - IT (624 KB)
- Korean - KR (624 KB)
- Portuguese - PT (624 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Shi G, et al. Two-generational reproductive toxicity assessment of 6:2 chlorinated polyfluorinated ether sulfonate (F-53B, a novel alternative to perfluorooctane sulfonate) in zebrafish. Environ Pollut. 2018 Dec;243(Pt B):1517-1527. [Content Brief]
[2]. Zhou X, et al. Subchronic reproductive effects of 6:2 chlorinated polyfluorinated ether sulfonate (6:2 Cl-PFAES), an alternative to PFOS, on adult male mice. J Hazard Mater. 2018;358:256-264. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7523 mL | 8.7616 mL | 17.5233 mL | 43.8082 mL |
| 5 mM | 0.3505 mL | 1.7523 mL | 3.5047 mL | 8.7616 mL | |
| 10 mM | 0.1752 mL | 0.8762 mL | 1.7523 mL | 4.3808 mL | |
| 15 mM | 0.1168 mL | 0.5841 mL | 1.1682 mL | 2.9205 mL | |
| 20 mM | 0.0876 mL | 0.4381 mL | 0.8762 mL | 2.1904 mL | |
| 25 mM | 0.0701 mL | 0.3505 mL | 0.7009 mL | 1.7523 mL | |
| 30 mM | 0.0584 mL | 0.2921 mL | 0.5841 mL | 1.4603 mL | |
| 40 mM | 0.0438 mL | 0.2190 mL | 0.4381 mL | 1.0952 mL | |
| 50 mM | 0.0350 mL | 0.1752 mL | 0.3505 mL | 0.8762 mL | |
| 60 mM | 0.0292 mL | 0.1460 mL | 0.2921 mL | 0.7301 mL | |
| 80 mM | 0.0219 mL | 0.1095 mL | 0.2190 mL | 0.5476 mL | |
| 100 mM | 0.0175 mL | 0.0876 mL | 0.1752 mL | 0.4381 mL |
6:2 Cl-PFAES Related Classifications
HY-W583749 Related Classifications
Powered by Bioz